Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.

"Competing Interests: MSK has filed for patent protection on behalf of M.M.D., D.R.V., M.R.M., N.K.C., S.M.C., S.M.L., D.A.S., and S.K. for inventions related to the work described in this paper. S.M.C. was named as an inventor on multiple patents filed by MSK, including those licensed to Y-mAbs Therapeutics. N.K.C. has a financial interest in Abpro-Labs, Biotec Pharmacon, Eureka Therapeutics, and Y-mAbs Therapeutics that may work in areas related to this paper. D.A.S. is an advisor to, or owns equity in, IOVA, ATNM, LNTH, Eureka Therapeutics, CoImmune, Atengen, Repertoire, and PFE, which may work in areas related to this paper. S.M.L. reports receiving commercial research grants from Y-mAbs Therapeutics, Genentech, Inc., WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc.; holding ownership interest/equity in Voreyda Theranostics Inc. and Elucida Oncology Inc., and holding stock in Y-mAbs Therapeutics. S.M.L. is the inventor and owner of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc., Y-mAbs Therapeutics Inc., and Elucida Oncology, Inc.; is or has served as a consultant to Cynvec LLC, Eli Lilly & Co., Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc., and Janssen Pharmaceuticals, Inc. SK has consulted for Telix Pharmaceuticals Ltd. and acknowledges support for investigator services from RayzeBio. The remaining authors report no competing interests."

"M.M.D. is supported by NIH F31 Ruth L. Kirschstein Predoctoral Individual National Research Service Award F31 CA239511. L.M.C. acknowledges support from the Ruth L. Kirschstein National Research Service Award postdoctoral fellowship (F32 EB025050). This study also received support from NIH/NCI R01 CA233896 (S.M.C.). D.A.S. is supported by NIH/NCI R35 CA241894, P01 CA23766, and R01 CA55349. S.K. is supported by NIH R37 CA262557, the NIH Lymphoma SPORE Career Enhancement Project Award (P50-CA192937), a Society of MSK research grant, Experimental Therapeutics Center Independent Investigator Award, the Steven A. Greenberg Lymphoma Research Award, the NCATS grant UL1-TR-002384 of the Clinical and Translational Science Center at Weill Cornell Medical College, and the TeamConnor Childhood Cancer Foundation. This work was also supported by NIH/NCI Cancer Center Support Grant P30 CA008748."